Author(s): Vina Neldi, Yulistiani


DOI: 10.52711/0974-360X.2022.00387   

Address: Vina Neldi1, Yulistiani2*
1Master of Clinical Pharmacy Programme, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
1,2Department of Clinical Pharmacy, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
*Corresponding Author

Published In:   Volume - 15,      Issue - 5,     Year - 2022

Bone is the part of body that most common for metastasis solid tumors. Bisphosphonates are an effective treatment for preventing bone damage events and improve quality of life patients. Zoledronic acid (ZOL) is the third generation of nitrogen-containing bisphosphonates (NBPs) that can inhibit osteoclasts in the process of bone resorption. Mechanism action of this drug related to affinity with hydroxyapatite crystals of bone, through a high bone turnover result in reducing speed of bone remodeling. This drug has higher affinity compared with other bisphosphonates for bonding hydroxyapatite . Zoledronic acid internalizes into osteoclasts, which disrupts the metabolic process and function of osteoclast cells and accelerates the occurrence of apoptosis. In the other hand it has adverse drug reactions mild to moderate which have reported but the mechanism still unclear such as hypocalcaemia and secondary hypophosphatemia, acute phase response (APR), renal toxicity, and osteonecrosis of the jaw (ONJ). Adverse drug reaction can cause harm to patient indeed arise death, highly recommended to offer monitoring for patients.

Cite this article:
Vina Neldi, Yulistiani. Zoledronic Acid use and Adverse Drug Reaction (ADR). Research Journal of Pharmacy and Technology. 2022; 15(5):2327-3. doi: 10.52711/0974-360X.2022.00387

Vina Neldi, Yulistiani. Zoledronic Acid use and Adverse Drug Reaction (ADR). Research Journal of Pharmacy and Technology. 2022; 15(5):2327-3. doi: 10.52711/0974-360X.2022.00387   Available on:

1.    Dubey S, Rastogi S, Sampath V, Khan SA, Kumar A. Role of intravenous zoledronic acid in management of giant cell tumor of bone- A prospective, randomized, clinical, radiological and electron microscopic analysis. J Clin Orthop Trauma. 2019;10(6):1021–6. DOI: 10.1016/j.jcot.2019.09.011
2.    Kathirvel S, Sahiti V, Suneetha A. Spectrophotometric Estimation of Risedronate Sodium in Bulk and Pharmaceutical Formulations using Multivariate Technique. Res J Pharm Technol. 2010 Jun;3(4):1209–12.
3.    Bergner R, Siegrist B, Gretz N., et al. Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.Pharmacol Res. 2015 May 30;99:16–22.
4.    Srivastava A, Mishra A, Rai AK. Synthesis, characterization and evaluation of ulcerogenic potential for NSAIDs-alendronate based prodrug. Res J Pharm Technol. 2020 Jan;13(5):2107–11. DOI: 10.5958/0974-360X.2020.00379.0
5.    Padmanabhan K, Paul J, Sudhakar S, Senthil Selvam P, Sathya Priya V, Veena Kirthika S. Which is more prevalent among the female population - Osteopenia or osteoporosis? A cross sectional study. Res J Pharm Technol. 2019 Mar 1;12(3):1163–8. DOI:10.5958/0974-360X.2019.00192.6
6.    Suman VB, Chattterjee PK, Vinodini NA, Kunal K, Gokul M, Bhat RM. Effect of variable diet and physical activity on bone mineral density in adults using peripheral–dexa scan. Res J Pharm Technol. 2018 Jun 1;11(6):2404–7. DOI:10.5958/0974-360X.2018.00444.4
7.    Radhakrishna B, Ashok M, Harish P., Jyothsna V., Gowda S. Indian Journals. Res J Pharmacol Pharmacodyn. 2011 Mar;3(6):329–33.
8.    Strukov VI, Kislov AI, Eremina N V., Deriabina GP, Sergeeva-Kondrachenko MY, Antropov AY, et al. The use of bone tissue non-steroid anabolizators in treatment of osteoporosis. Res J Pharm Technol. 2019;12(5):2195–9. DOI: 10.5958/0974-360X.2019.00366.4
9.    Nugraha AP, Rezkita F, Puspitaningrum MS, Luthfimaidah MS, Narmada IB, Prahasanti C, et al. Gingival mesenchymal stem cells and chitosan scaffold to accelerate alveolar bone remodelling in periodontitis: A narrative review. Res J Pharm Technol. 2020 May 1;13(5):2502–6. DOI: 10.5958/0974-360X.2020.00446.1
10.    CLEZARDIN P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev. 2005;31:1–8. DOI: 10.1016/j.ctrv.2005.09.002
11.    Rogers MJ, Gordon S, Benford HL, et al. Bisphosphonates.<2961::AID-CNCR12>3.0.CO;2-L
12.    Munns CF, Rajab MH, Hong J, Briody J, Högler W, McQuade M, et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone. 2007;41(3):366–70.DOI: 10.1016/j.bone.2007.05.002
13.    Yachoui R. Early onset acute tubular necrosis following single infusion of zoledronate. Clin Cases Miner Bone Metab. 2016;13(2):154–6.DOI: 10.11138/ccmbm/2016.13.2.154
14.    Carbonare LD, Mottes M, Malerba G, Mori A, Zaninotto M, Plebani M, et al. Enhanced osteogenic differentiation in zoledronate-treated osteoporotic patients. Int J Mol Sci. 2017;18(6). DOI: 10.3390/ijms18061261
15.    Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45. DOI: 10.4065/83.9.1032
16.    Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, et al. Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid. J Pharmacol Exp Ther [Internet]. 2002 Sep 1 [cited 2021 Oct 18];302(3):1055–61. Available from: 10.1124/jpet.102.035295
17.    Bahşi R, Atmiş V, Turgut T, Mut Sürmeli D, Coşarderelioğlu Ç, Selvi Öztorun H, et al. May zoledronic acid have negative effects on cognition and muscle performance? Ir J Med Sci. 2020;189(1):191–6.DOI: 10.1007/s11845-019-02086-5
18.    Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int [Internet]. 2008 [cited 2021 Oct 18];74:1385–93. Available from: 10.1038/ki.2008.356
19.    Verhulst A, Sun S, McKenna CE, D’Haese PC. Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound. PLoS One. 2015;10(3):1–19. doi: 10.1371/journal.pone.0121861
20.    Ott SM. Bisphosphonate safety and efficacy in chronic kidney disease. Kidney Int. 2012;82(8):833–5. DOI: 10.1038/ki.2012.253
21.    Srivastava T, Garg U, Ruiz M, Dai H, Alon US. Serum 25(OH)-vitamin D level in children: Is there a need to change the reference range based on 2011 institute of medicine report? Clin Pediatr (Phila). 2013;52(2):178–82. DOI: 10.1177/0009922811425954
22.    Osborne A. Zoledronic acid. Clin J Oncol Nurs. 2002;6(6):365–6. doi: 10.1016/j.jbo.2015.08.001
23.    Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, et al. Zoledronic acid and renal toxicity: Data from French adverse effect reporting database. Ann Pharmacother. 2005;39(7–8):1194–7. DOI: 10.1345/aph.1E589
24.    Demirtas D, Bilir C, Demirtas AO, Engin H. The effects of zoledronic acid on ECG: A prospective study on patients with bone metastatic cancer. Clin Cases Miner Bone Metab. 2017;14(1):35–9.doi: 10.11138/ccmbm/2017.14.1.035
25.    Glen S. M, Paul. L. F, Jay .I. S, Cheryl .L. K, Jai. R, Winicjusz. P, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281–9. DOI: 10.1046/j.1523-1755.2003.00071.x
26.    Torimoto K, Okada Y, Arao T, Mori H, Tanaka Y. A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome. Endocr J. 2012;59(12):1051–6. DOI: 10.1507/endocrj.ej12-0166
27.    Zekria J, Mansour M, Karim SM. The anti-tumour effects of zoledronic acid. J Bone Oncol. 2014;3(1):25–35. DOI: 10.1016/j.jbo.2013.12.001
28.    Manuel SH, Groba MM, Gonzalez D. Zoledronic acid in the treatment. 2010;2(Supl 4):21–30.
29.    Sarkar M, Bhardwaj R, Madabhavi I, Khatana J. Osteoporosis in chronic obstructive pulmonary disease. Clin Med Insights Circ Respir Pulm Med. 2015;9:5–21. doi: 10.4137/CCRPM.S22803
30.    Gong L, Altman RB, Klein TE. Bisphosphonates pathway. Pharmacogenet Genomics. 2011;21(1):50–3. DOI: 10.1097/FPC.0b013e328335729c
31.    Thangavelu T, Johnson-Rabbett B, Magar RR, Khowaja A. Severe Systemic Inflammatory Response Syndrome with Multi-Organ Failure Following Zoledronic ACID Infusion. AACE Clin Case Reports. 2018;4(1):26–9. DOI:10.4158/EP161734.CR
32.    Durgia H, Sahoo J, Kamalanathan S, Palui R, Sridharan K, Raj H. Role of bisphosphonates in the management of acute Charcot foot. World J Diabetes. 2018;9(7):115–26. doi: 10.4239/wjd.v9.i7.115
33.    Roelofs AJ, Jauhiainen M, Mönkkönen H, Rogers MJ, Mönkkönen J, Thompson K. Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol. 2009;144(2):245–50. DOI: 10.1111/j.1365-2141.2008.07435.x
34.    Scala R, Maqoud F, Angelelli M, Latorre R, Perrone MG, Scilimati A, et al. Zoledronic acid modulation of TRPV1 channel currents in osteoblast cell line and native rat and mouse bone marrow-derived osteoblasts: Cell proliferation and mineralization effect. Cancers (Basel). 2019;11(2). doi: 10.3390/cancers11020206
35.    Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for Osteoporosis — Where Do We Go from Here? N Engl J Med. 2012;366(22):2048–51. DOI: 10.1056/NEJMp1202619
36.    Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95(9):4380–7. DOI: 10.1210/jc.2010-0597
37.    Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B, et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood. 2007;110(3):921–7. DOI: 10.1182/blood-2006-09-044321
38.    Barba-Recreo P, Del Castillo Pardo De Vera JL, García-Arranz M, Yébenes L, Burgueño M. Zoledronic acid - Related osteonecrosis of the jaws. Experimental model with dental extractions in rats. J Cranio-Maxillofacial Surg. 2014;42(6):744–50. DOI: 10.1016/j.jcms.2013.11.005
39.    Ouyang Z, Li H, Zhai Z, Xu J, Dass CR, Qin A, et al. Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma. Curr Drug Targets. 2018;19(5):409–21. DOI: 10.2174/1573399811666150615145409
40.    Bonneville M, Scotet E. Human Vγ9Vδ2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol. 2006;18(5):539–46. DOI: 10.1016/j.coi.2006.07.002
41.    Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol. 2006;69(5):1624–32. DOI: 10.1124/mol.105.020776
42.    Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42(11):1228–36. DOI: 10.1177/009127002762491316
43.    Tucci JR, Bone HG, Su G, Tan M, Ozturk ZE, Aftring P. Effect of zoledronic acid on serum calcium in Paget’s disease patients after educational strategies to improve calcium and vitamin D supplementation. Ther Adv Endocrinol Metab. 2015;6(4):155–62. DOI: 10.1177/2042018815579020
44.    Luedders DW, Steinhoff J, Thill M, Rody A, Bohlmann MK. Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases. Anticancer Res. 2015;35(3):1797–802.
45.    Crotti C, Watts NB, De Santis M, Ceribelli A, Fabbriciani G, Cavaciocchi F, et al. Acute phase reactions after zoledronic acid infusion: Protective role of 25-hydroxyvitamin D and previous oral bisphosphonate therapy. Endocr Pract. 2018;24(5):405–10. DOI: 10.4158/EP161638.OR
46.    Mânea HC, Urechescu HC, Balica NC, Pricop MO, Baderca F, Poenaru M, et al. Bisphosphonates-induced osteonecrosis of the jaw – Epidemiological, clinical and histopathological aspects. Rom J Morphol Embryol. 2018;59(3):825–31.
47.    Al Elq AH. Symptomatic hypocalcemia associated with zoledronic acid treatment for Osteoporosis: A case report. Oman Med J. 2013;28(2):2–4. doi: 10.5001/omj.2013.42
48.    Kim D. Severe Hypocalcemia After the Administration of Zoledronic Acid for Osteoporotic Fracture. J Med Cases. 2016;7(10):441–4.
49.    Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314–21. DOI: 10.1200/JCO.2005.05.116
50.    McKay RR, Lin X, Perkins JJ, Heng DYC, Simantov R, Choueiri TK. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol. 2014;66(3):502–9. DOI: 10.1016/j.eururo.2014.02.040
51.    Harini K, Vishnu Priya V, Gayathri R. Awareness of importance of vitamin d among dental students in a dental school – A survey. Res J Pharm Technol. 2016;9(8):1133–6. DOI: 10.5958/0974-360X.2016.00215.8
52.    Ding X, Fan Y, Ma F, Li Q, Wang J, Zhang P, et al. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis. Breast. 2012;21(4):544–9. DOI: 10.1016/j.breast.2012.04.008
53.    Papapetrou PD. Bisphosphonate-associated adverse events. 2009;8(2):96–110. DOI: 10.14310/horm.2002.1226
54.    Zuradelli M, Masci G, Biancofiore G., et al. High Incidence of Hypocalcemia and Serum Creatinine Increase in Patients with Bone Metastases Treated with Zoledronic Acid. Oncologist. 2009;14(5):548–56. DOI: 10.1634/theoncologist.2008-0227
55.    Hamdy RC. Zoledronic acid: Clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther. 2010;4:321–35. DOI: 10.2147/DDDT.S6287
56.    Roelofs AJ, Thompson K, Gordon S, Rogers MJ, Boyce, Roodman, et al. Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res. 2006;12(20 PART 2). DOI: 10.1158/1078-0432.CCR-06-0843
57.    Coleman R, Cook R, Hirsh V, Major P, Lipton A. Zoledronic acid use in cancer patients. Cancer. 2011;117(1):11–23.
58.    Deng J, Cai D, Jie S, Chen E, Cai X, Li Y. Sequential Treatment Reduces the Acute Phases of Adverse Effect of Zoledronic Acid in First Time Users. Open J Prev Med. 2018;08(07):189–205. DOI:10.4236/ojpm.2018.87018
59.    Niveditha, Srikanth, Singh H, Srinivasa R. A prospective case-control study to evaluate the effect of chronic anti-epileptic therapy on bone turnover markers. Res J Pharm Technol. 2013;6(12):1321–4.
60.    Popp AW, Senn R, Curkovic I, Senn C, Buffat H, Popp PF, et al. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int. 2017;28(6):1995–2002. DOI: 10.1007/s00198-017-3992-5
61.    Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13(15):4482–6. DOI: 10.1158/1078-0432.CCR-07-0551
62.    Cheng L, Ge M, Lan Z, Ma Z, Chi W, Kuang W, et al. Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018;92(1):469–85. DOI: 10.1007/s00204-017-2048-0
63.    Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA. Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Rev Hematol. 2018;11(11):881–8. DOI: 10.1080/17474086.2018.1531702
64.    De Barros Silva PG, Ferreira Junior AEC, Teófilo CR, Barbosa MC, Lima Júnior RCP, Sousa FB, et al. Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosis. Arch Oral Biol. 2015;60(9):1237–45. DOI: 10.1016/j.archoralbio.2015.05.015
65.    Lehrer S, Montazem A, Ramanathan L., et al. Bisphosphonate-Induced Osteonecrosis of the Jaws, Bone Markers, and a Hypothesized Candidate Gene. J Oral Maxillofac Surg. 2009;67(1):159–61. DOI: 10.1016/j.joms.2008.09.015
66.    Arunkumar P., Mukund H, Radheshyam N, Belliyappa M. Clinical Evaluation of Cisplatin Induced Nephrotoxicity Characterized By Electrolyte Disturbances-Indian Journals. Asian J Res Pharm Sci. 2011 Jun;1(4):100–4.
67.    Marofi F, Hassanzadeh A, Solali S, Vahedi G, Mousavi Ardehaie R, Salarinasab S, et al. Epigenetic mechanisms are behind the regulation of the key genes associated with the osteoblastic differentiation of the mesenchymal stem cells: The role of zoledronic acid on tuning the epigenetic changes. J Cell Physiol. 2019;234(9):15108–22. DOI: 10.1002/jcp.28152
68.    Müller F, Appelt KA., et al. Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee. Knee Surgery, Sport Traumatol Arthrosc. 2020;28(2):408–17. DOI: 10.1007/s00167-019-05598-w
69.    Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F, Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol. 2007;71(1):333–43. DOI: 10.1124/mol.106.028837
70.    Tufano A, Rendina D, Conca P, Matani B, Di Minno G. Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis. Intern Emerg Med. 2019;(0123456789):3–5. DOI:10.1007/s11739-019-02048-w
71.    Jennings P, Crean D, Aschauer L, Limonciel A, Moenks K, Kern G, et al. Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015;89(1):101–6. DOI: 10.1007/s00204-014-1237-3
72.    Stresing V, Fournier PG, Bellahcène A, Benzaïd I, Mönkkönen H, Colombel M, et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone. 2011;48(2):259–66.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available